Poster
T-DXd
ASCO GI 2026 | January 8-10, 2026
Gastric Cancer
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) + chemotherapy ± pembrolizumab versus chemotherapy + trastuzumab ± pembrolizumab in first-line metastatic HER2+ gastric or gastroesophageal junction cancer: DESTINY-Gastric05
Kohei Shitara
Poster
T-DXd
ASCO GI 2026 | January 8-10, 2026
Gastric Cancer
Exploratory analysis of HER2 status based on central and local testing results from the DESTINY-Gastric04 study
Kohei Shitara
Poster
T-DXd
ASCO GI 2026 | January 8-10, 2026
Gastric Cancer
First-line trastuzumab deruxtecan with volrustomig and fluoropyrimidine in patients with HER2-low gastric cancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma: DESTINY-Gastric03 part 5
Yelena Y. Janjigian
Poster
T-DXd
ASCO GI 2026 | January 8-10, 2026
Gastric Cancer
GEMINI-PeriOp Gastric: A phase 2 study of novel agent-based combinations as perioperative therapy for previously untreated, locally advanced resectable gastric, gastroesophageal junction, or esophageal adenocarcinoma
Ziyu Li